The management of adult aggressive non-Hodgkin's lymphomas.

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Critical reviews in oncology/hematology

• Publication date

  2000-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S1040-8428(99)00037-2PMID 10863150
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A randomized study of radiotherapy versus radiotherapy plus chemotherapy in stage I‐II non‐hodgkin's lymphomas

  2006cited by this paper
• Intensive chemotherapy for adult lymphoblastic lymphomas

  2004cited by this paper
• m-BACOD chemotherapy for intermediate- and high-grade non-Hodgkin's lymphoma

  2004cited by this paper
• Phase I study of bryostatin 1 in patients with relapsed non-Hodgkin's lymphoma and chronic lymphocytic leukemia.

  1998cited by this paper
• Primary diffuse large B-cell lymphoma of the mediastinum: outcome following high-dose chemotherapy and autologous hematopoietic cell transplantation.

  1998cited by this paper
• Phase I trial of a ligand fusion-protein (DAB389IL-2) in lymphomas expressing the receptor for interleukin-2.

  1998cited by this paper
• Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases.

  1998cited by this paper
• CHOP is the standard regimen in patients > or = 70 years of age with intermediate-grade and high-grade non-Hodgkin's lymphoma: results of a randomized study of the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Study Group.

  1998cited by this paper
• A clinical evaluation of the International Lymphoma Study Group Classification of non-Hodgkin's lymphoma: a report of the Non-Hodgkin's Lymphoma Classification Project

  1997cited by this paper
• Early restaging gallium scans predict outcome in poor-prognosis patients with aggressive non-Hodgkin's lymphoma treated with high-dose CHOP chemotherapy.

  1997cited by this paper
• Intensified and high-dose chemotherapy with granulocyte colony-stimulating factor and autologous stem-cell transplantation support as first-line therapy in high-risk diffuse large-cell lymphoma.

  1997cited by this paper
• 3'-Azido 3'-deoxythymidine + methotrexate as a novel antineoplastic combination in the treatment of human immunodeficiency virus-related non-Hodgkin's lymphomas.

  1997cited by this paper
• Treatment for non-Hodgkin's lymphoma (stage I, II) of the elderly: usefulness of local and regional irradiation and reduced dose chemotherapy.

  1997cited by this paper
• Immunotherapy with recombinant human interleukin-2 and recombinant interferon-alpha in lymphoma patients postautologous marrow or stem cell transplantation.

  1997cited by this paper
• New drugs in non-Hodgkin's lymphoma.

  1997cited by this paper
• Mutations of the p53 gene as a prognostic factor in aggressive B-cell lymphoma.

  1997cited by this paper
• A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project.

  1997cited by this paper
• Magnetic resonance imaging of the bone marrow in hematologic malignancies.

  1997cited by this paper
• Elderly patients with aggressive non-Hodgkin's lymphoma: disease presentation, response to treatment, and survival--a Groupe d'Etude des Lymphomes de l'Adulte study on 453 patients older than 69 years.

  1997influential reference
• High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma.

  1997cited by this paper
• Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.

  1997cited by this paper
• Elevated serum CD44 level is associated with unfavorable outcome in non-Hodgkin's lymphoma.

  1997cited by this paper
• Phase II trial of docetaxel in non-Hodgkin's lymphomas: a study of the Cancer and Leukemia Group B.

  1997cited by this paper
• Prognostic significance of Bax protein expression in diffuse aggressive non-Hodgkin's lymphoma.

  1997cited by this paper
• Randomized trial with or without granulocyte colony-stimulating factor as adjunct to induction VNCOP-B treatment of elderly high-grade non-Hodgkin's lymphoma.

  1997cited by this paper
• Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma: updated results of the prospective study LNH87-2. Groupe d'Etude des Lymphomes de l'Adulte.

  1997cited by this paper
• Paclitaxel activity for the treatment of non‐Hodgkin's lymphoma: final report of a phase II trial

  1997cited by this paper
• Primary anaplastic large-cell lymphoma in adults: clinical presentation, immunophenotype, and outcome.

  1997cited by this paper
• Intensive sequential chemotherapy with repeated blood stem-cell support for untreated poor-prognosis non-Hodgkin's lymphoma.

  1997cited by this paper
• Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma.

  1997cited by this paper
• Cyclophosphamide, doxorubicin, vincristine, prednisone dose intensification with granulocyte colony-stimulating factor markedly depletes stem cell reserve for autologous bone marrow transplantation.

  1997cited by this paper
• Comparative diagnostic accuracy of magnetic resonance imaging and immunoscintigraphy for detection of bone marrow involvement in patients with malignant lymphoma.

  1997cited by this paper
• IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma.

  1997cited by this paper
• Clinical and prognostic significance of femoral marrow magnetic resonance imaging in patients with malignant lymphoma.

  1997cited by this paper
• Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Groupe d'Etude des Lymphomes de l'Adulte (GELA).

  1996cited by this paper
• Survival benefit from high-dose therapy with autologous blood progenitor-cell transplantation in poor-prognosis non-Hodgkin's lymphoma.

  1996cited by this paper
• Phase I trial of dose escalation with growth factor support in patients with previously untreated diffuse aggressive lymphomas: determination of the maximum-tolerated dose of ProMACE-CytaBOM.

  1996cited by this paper
• Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma.

  1996cited by this paper
• Allogeneic bone marrow transplantation for poor-prognosis lymphoma: response, toxicity and survival depend on disease histology.

  1996cited by this paper
• Primary mediastinal large B-cell lymphoma. A clinicopathologic study of 141 cases compared with 916 nonmediastinal large B-cell lymphomas, a GELA ("Groupe d'Etude des Lymphomes de l'Adulte") study.

  1996cited by this paper
• Immunodetection of apoptosis-regulating proteins in lymphomas from patients with and without human immunodeficiency virus infection.

  1996cited by this paper
• Management of histologically indolent non-Hodgkin's lymphomas.

  1996cited by this paper
• Pilot trial of infusional cyclophosphamide, doxorubicin, and etoposide plus didanosine and filgrastim in patients with human immunodeficiency virus-associated non-Hodgkin's lymphoma.

  1996cited by this paper
• Vaccination of patients with B–cell lymphoma using autologous antigen–pulsed dendritic cells

  1996cited by this paper
• Non-Hodgkin's Lymphoma in the Elderly.

  1996cited by this paper
• The Role of Intensive Therapy and Autologous Blood and Marrow Transplantation for Chemotherapy‐Sensitive Relapsed and Primary Refractory Non‐Hodgkin’s Lymphoma: Identification of Major Prognostic Groups

  1996cited by this paper
• 3 Management of histologically indolent non-Hodgkin's lymphomas

  1996cited by this paper
• High-dose chemotherapy followed by autologous bone marrow transplantation versus dexamethasone, cisplatin, and cytarabine in aggressive non-Hodgkin's lymphoma with partial response to front-line chemotherapy: a prospective randomized italian multicenter study.

  1996cited by this paper
• Primary systemic CD30 (Ki-1)-positive anaplastic large cell lymphoma of the adult: sequential intensive treatment with the F-MACHOP regimen (+/- radiotherapy) and autologous bone marrow transplantation.

  1996cited by this paper
• No effect of 96-hour paclitaxel infusion in patients with relapsed non-Hodgkin's lymphoma refractory to a 3-hour infusion schedule.

  1996cited by this paper
• Lymphoma classification--the gap between biology and clinical management is closing.

  1996cited by this paper
• Three-hour paclitaxel infusion in patients with refractory and relapsed non-Hodgkin's lymphoma.

  1995cited by this paper
• Phase II study of paclitaxel in relapsed non-Hodgkin's lymphomas.

  1995cited by this paper
• Prolonged impairment of hematopoiesis after high-dose therapy followed by autologous bone marrow transplantation.

  1995cited by this paper
• A phase II trial of mesna/ifosfamide, mitoxantrone and etoposide for refractory lymphomas.

  1995cited by this paper
• BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma.

  1995cited by this paper
• High-dose chemotherapy and autologous bone marrow transplantation for malignant lymphomas.

  1995cited by this paper
• Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.

  1995influential reference
• Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma.

  1995cited by this paper
• Treatment of Adult T-Cell Leukemia-Lymphoma with Zidovudine and Interferon Alfa

  1995cited by this paper
• Results of a salvage treatment program for relapsing lymphoma: MINE consolidated with ESHAP.

  1995cited by this paper
• Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin's lymphoma.

  1995cited by this paper
• Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 31-1995. A 43-year-old man with multifocal neurologic problems and confusion.

  1995cited by this paper
• High-dose CHOP as initial therapy for patients with poor-prognosis aggressive non-Hodgkin's lymphoma: a dose-finding pilot study.

  1995cited by this paper
• Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine.

  1995cited by this paper
• Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy.

  1995cited by this paper
• Lymphoblastic lymphoma and Burkitt's lymphoma in Caucasian adults: please don't forget the pediatric experience.

  1995cited by this paper
• Small noncleaved cell lymphoma and leukemia in adults. A retrospective study of 65 adults treated with the LMB pediatric protocols.

  1995cited by this paper
• Fourteen years of high-dose CHOP (ACVB regimen): preliminary conclusions about the treatment of aggressive-lymphoma patients. Hamilton Fairley Award Lecture, European Society for Medical Oncology Meeting, Lisbon, November 21, 1994.

  1995cited by this paper
• Chemotherapy combined with zidovudine and GM-CSF in human immunodeficiency virus-related non-Hodgkin's lymphoma.

  1995cited by this paper
• Hydrolysis studies on oleamide in simulated gastrointestinal fluids.

  1995cited by this paper
• Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas.

  1995cited by this paper
• Evaluation of a somatostatin analog in the treatment of lymphoproliferative disorders: results of a phase II North Central Cancer Treatment Group trial.

  1995cited by this paper
• T-cell-rich B-cell lymphomas: diagnosis and response to therapy of 44 patients.

  1995cited by this paper
• Prognostic factors in aggressive non-Hodgkin's lymphoma: who has "high-risk" disease?

  1994cited by this paper
• Escalating dose of mitoxantrone with high-dose cyclophosphamide, carmustine, and etoposide in refractory lymphoma patients undergoing autologous bone marrow transplantation.

  1994cited by this paper
• Interleukin-2 treatment in lymphoma: a phase II multicenter study.

  1994cited by this paper
• Escalating dose of mitoxantrone with high-dose cyclophosphamide, carmustine, and etoposide in patients with refractory lymphoma undergoing autologous bone marrow transplantation.

  1994cited by this paper
• Phase I/II study of cyclophosphamide, carboplatin, and etoposide and autologous hematopoietic stem-cell transplantation with posttransplant interferon alfa-2b for patients with lymphoma and Hodgkin's disease.

  1994cited by this paper
• Randomized comparison of MACOP-B with CHOP in patients with intermediate-grade non-Hodgkin's lymphoma. The Australian and New Zealand Lymphoma Group.

  1994cited by this paper
• Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies.

  1994cited by this paper
• Myelodysplastic syndrome as a late complication following autologous bone marrow transplantation for non-Hodgkin's lymphoma.

  1994cited by this paper
• Phase I study of alpha-interferon augmentation of cyclosporine-induced graft versus host disease in recipients of autologous bone marrow transplantation.

  1994cited by this paper
• Autologous bone marrow transplantation in poor-risk high-grade non-Hodgkin's lymphoma in first complete remission. Newcastle and Northern Lymphoma Group.

  1994cited by this paper
• High-dose therapy and autologous bone marrow transplantation in first complete remission for adult patients with high-grade non-Hodgkin's lymphoma: the EBMT experience. Lymphoma Working Party of the European Group for Bone Marrow Transplantation.

  1994cited by this paper
• Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patients with non-Hodgkin's lymphoma.

  1994cited by this paper
• Prognostic factors in patients who received autologous bone marrow transplantation for non-Hodgkin's lymphoma. Report of 104 patients from the Spanish Cooperative Group GEL/TAMO.

  1994cited by this paper
• Rearrangement of the bcl-6 gene as a prognostic marker in diffuse large-cell lymphoma.

  1994cited by this paper
• Myelodysplastic syndrome after autologous bone marrow transplantation: an additional late complication of curative cancer therapy.

  1994cited by this paper
• Comparable prognostic factors and survival in elderly patients with aggressive non-Hodgkin's lymphoma treated with standard-dose adriamycin-based regimens.

  1994cited by this paper
• Comparison of autologous bone marrow transplantation with sequential chemotherapy for intermediate-grade and high-grade non-Hodgkin's lymphoma in first complete remission: a study of 464 patients. Groupe d'Etude des Lymphomes de l'Adulte.

  1994cited by this paper
• ESHAP--an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study.

  1994cited by this paper
• Comparison of peripheral blood stem-cell and autologous bone marrow transplantation for lymphoma patients: a case-controlled analysis of the EBMT Registry data. Lymphoma Working Party of the EBMT.

  1994cited by this paper
• Intravascular lymphomatosis: a clinicopathologic study of 10 cases and assessment of response to chemotherapy.

  1994cited by this paper
• A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group.

  1994cited by this paper
• Significance of a partial or slow response to front-line chemotherapy in the management of intermediate-grade or high-grade non-Hodgkin's lymphoma: a literature review.

  1994cited by this paper
• High-dose therapy and autologous bone marrow transplantation in first complete remission for adult patients with high-grade non-Hodgkin's lymphoma : the EBMT experience

  1994cited by this paper
• Second cancers among long-term survivors of non-Hodgkin's lymphoma.

  1993cited by this paper
• High-dose chemotherapy and autologous hematopoietic stem-cell transplantation for aggressive non-Hodgkin's lymphoma.

  1993cited by this paper
• Combined modality treatment with primary CHOP chemotherapy followed by locoregional irradiation in stage I or II histologically aggressive non-Hodgkin's lymphomas.

  1993cited by this paper

• Cervical Lymph Node Excision – A Retrospective Analysis of Differential Diagnoses and Prognostic Variables

  2018cites this paper
• Prognostic value of comorbidity for auto-SCT eligibility and outcome in relapsed or refractory aggressive non-Hodgkin's lymphoma

  2011cites this paper
• Lymphomes malins non hodgkiniens Non-hodgkin ’ s lymphomas

  2010cites this paper
• [Non-hodgkin's lymphomas].

  2010cites this paper
• Modulation of radiosensitivity in Chinese hamster lung fibroblasts by cisplatin.

  2008cites this paper
• T-cell lymphoma – case report

  2008cites this paper
• Therapeutic results in patients with relapsed diffuse large B cell Non‐Hodgkin's lymphoma achieving complete response only after autologous stem cell transplantation

  2006cites this paper
• Cell cycle dependent phosphorylation and focus-formation of histone H2AX in X-irradiated malignant B-lymphocyte cell lines : detection and repair of ionizing radiation induced DNA double strand breaks

  2005influential citation
• A mathematical model of Doxorubicin treatment efficacy for non-Hodgkin ’ s lymphoma : investigation of the current protocol through theoretical modelling results

  2005cites this paper
• A mathematical model of Doxorubicin treatment efficacy for non-Hodgkin’s lymphoma: Investigation of the current protocol through theoretical modelling results

  2005cites this paper
• Ifosfamide, Epirubicin and Etoposide (IEV) Regimen as Salvage and Mobilization Therapy for Refractory or Early Relapsing Patients with Aggressive Non-Hodgkin's Lymphoma

  2004cites this paper
• Towards whole-organ modelling of tumour growth.

  2004cites this paper
• The comparison of spontaneous LDH release activity from cultured PBMC with sera LDH activity in non-Hodgkin’s lymphoma patients

  2004cites this paper
• The Use of Hybrid Cellular Automaton Models for Improving Cancer Therapy

  2004cites this paper
• Autologous bone marrow transplant in a patient with sickle cell disease and diffuse large B-cell lymphoma.

  2003cites this paper
• Bilateral Hearing Loss During Vincristine Therapy: A Case Report

  2003cites this paper
• Highlights From: 6th European Hematology Association Meeting, Frankfurt, Germany June 21–24, 2001

  2001cites this paper
• The French ACVBP Regimen Improves Event-Free Survival for Poor Prognosis Patients with Aggressive NHL as Compared to Standard CHOP

  2001cites this paper
• Treatment of human immunodeficiency virus-related lymphoma.

  2001cites this paper
• [Intraoral non-Hodgkin's lymphoma. Presentation of 4 clinical cases].

  2001cites this paper
• Linfoma no-hodgkin intraoral. presentación de 4 casos clínicos

  2001cites this paper
• Rituximab Plus CHOP is Superior to CHOP Alone for Aggressive Diffuse Large B-Cell Lymphoma: Interim Results of a GELA Phase III Trial

  2001cites this paper
• NON-HODGKIN LENFOMA TANILI HASTALARIMIZIN RETROSPEKTİF DEĞERLENDİRİLMESİ RETROSPECTIVE EVALUATION OF OUR PATIENTS WITH DIAGNOSIS NON-HODGKIN LYMPHOMA

  year unknowncites this paper